Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment-Reference-Cited by-同舟云学术

Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment

Published:2015-03 Issue:3 Volume:43 Page:168-176.e2
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

An Gang,Acharya Chirag,Deng Shuhui,Yi Shuhua,Xu Yan,Qin Xiaoqi,Sui Weiwei,Li Zengjun,Shi Lihui,Zang Meirong,Feng Xiaoyan,Hao Mu,Zou Dehui,Zhao Yaozhong,Qi Junyuan,Cheng Tao,Ru Kun,Wang Jianxiang,Tai Yu-Tzu,Qiu Lugui

Funder

National Natural Science Fund

Clinical Research Program of the Ministry of Health

Special Key Anticancer Research and Development Program of Tianjin Municipality

Union Youth Research Fund of Peking Union Medical College

Doctoral Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference29 articles.

1. Multiple myeloma;Palumbo;N Engl J Med,2011

2. Latest advances and current challenges in the treatment of multiple myeloma;Mahindra;Nat Rev Clin Oncol,2012

3. Proteasome inhibitors in multiple myeloma: 10 years later;Moreau;Blood,2012

4. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma;Mitsiades;J Clin Oncol,2011

5. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials;Jagannath;Leukemia,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10

2. Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy;Cell Biology and Translational Medicine, Volume 20;2023

3. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?;Clinical Lymphoma Myeloma and Leukemia;2022-07

4. ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells;Scientific Reports;2022-02-10

5. Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials;Journal of Cancer;2020